Staxom

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Staxom

Property Description
Active ingredient Moxifloxacin hydrochloride
Form Tablet, Solution for intravenous infusion
Pharmacological class Fluoroquinolone Antibiotic
General purpose Elimination of bacterial infections
Origin Synthetic compound

Staxom is a prescription-only medication whose active component is moxifloxacin, a synthetic compound categorized as a systemic antibacterial within the fluoroquinolone antibiotic class. Its fundamental purpose is to manage various bacterial infections by eradicating the harmful microorganisms responsible for causing the illness.

What Type of Antibiotic is Staxom?

Staxom belongs to the modern generation of the broader quinolone family of antimicrobials. The specific structure of moxifloxacin provides a broad-spectrum antibiotic capability, meaning it is effective against a wide variety of bacterial strains. Moxifloxacin is an anti-infective compound with recognized efficacy across various systemic applications. This means the medication acts throughout the body to fight off pathogenic threats, and is clinically recognized for its utility in treating infections requiring extensive microbial coverage.

What is the General Purpose of Moxifloxacin?

The general purpose of moxifloxacin is to provide bactericidal action, directly resulting in the death of the targeted bacterial cells. This mechanism involves interrupting the bacteria's essential processes, such as DNA synthesis, thereby preventing their survival and replication. Moxifloxacin possesses a potent bactericidal effect against susceptible pathogens. This confirms the drug’s ability to actively destroy the source of the infection, which is often utilized in scenarios where a patient requires intervention for a serious systemic bacterial illness.

Dosage Forms of Staxom

Moxifloxacin is supplied in distinct pharmaceutical preparations: it is available for oral intake as a tablet and formulated as an aqueous solution for intravenous administration. This dual availability ensures that the medication can be efficiently delivered systemically, whether through absorption via the digestive tract or direct introduction into a vein. This flexibility in route of administration is a key feature, allowing healthcare providers to transition the treatment from the intravenous (IV) form, used in acute settings, to the more convenient oral form once the patient's condition stabilizes.

What side effects are possible with Staxom?

Possible Side Effects and Safety Information

The safety characteristics of Staxom, which contains moxifloxacin, are officially defined by regulatory authorities like the FDA and EMA. Adverse reactions are classified by how often they appear and the body system they affect (System-Organ-Class).

Common adverse reactions (occurring in 1% to <10% of users in clinical trials) include nausea, diarrhea, headache, dizziness, vomiting, and abdominal pain. Elevated liver transaminases are also commonly documented.

Serious and potentially disabling adverse reactions are also officially documented. These include tendinitis and tendon rupture (which can occur during or up to several months after treatment), peripheral neuropathy (nerve damage that may be long-lasting), and serious effects on the Central Nervous System (CNS) such as seizures, confusion, and psychotic reactions. The medication is also associated with QT prolongation, which can lead to serious and life-threatening heart rhythm abnormalities, such as Torsade de Pointes.

Safety Considerations for Specific Populations

Official safety statements note that the risk of tendon adverse reactions is increased in specific groups, including older adults (over 60 years of age) and solid organ transplant recipients. Use is restricted or contraindicated in individuals with a history of quinolone-related tendon disorders or pre-existing conditions that predispose to serious heart rhythm problems, such as documented QT prolongation or uncorrected hypokalemia. Psychiatric reactions may occur even after the first dose.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Staxom (Moxifloxacin) overdose focuses primarily on the risk of electrical changes in the heart and the need for immediate medical monitoring.

Overdose Scope Official Regulatory Information
Documented Overdose Presentations No specific symptoms are consistently reported across all acute overdose cases, but signs of central nervous system (CNS) effects and gastrointestinal disturbances are possible.
Physiological Systems Affected Primarily the cardiovascular system (heart rhythm) and the central nervous system.
Dose-Related or Exposure-Related Factors Overdose can lead to an increase in the QTc interval on the electrocardiogram (ECG), which indicates a possible effect on heart rhythm.
Population-Specific Overdose Notes None specifically described within the overdose management section.
Emergency-Response Statements Treatment must be supportive and include close monitoring of the heart rhythm (ECG) to detect any QTc prolongation. Activated charcoal can be administered shortly after oral ingestion.
When Immediate Medical Help Is Required Contact a physician, hospital, or emergency services immediately if an overdose is suspected, even if no symptoms are present.

Official Overdose Statements

  • Overdose may result in a potentially significant prolongation of the QTc interval on the heart's electrical tracing.
  • Medical management requires prompt contact with emergency services or a poison control center.
  • Treatment of overdose is supportive, and continuous ECG monitoring is required due to the risk of QTc changes.
  • Use of activated charcoal may be considered shortly after oral overdose to reduce absorption.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile by prioritizing the risk of cardiac toxicity, specifically QTc prolongation, necessitating immediate clinical attention. This cardiac risk mandates that medical professionals continuously monitor the patient’s ECG to manage potential rhythm disturbances resulting from the overdose. Consequently, official guidance requires patients to seek immediate medical help upon suspected over-ingestion, regardless of initial symptom presentation.

Therapeutic Uses of Staxom

Staxom: Main Uses and Therapeutic Benefits

The drug's function is consistent with the therapeutic domain often addressed by anti-inflammatory treatments. Staxom is commonly used to help manage symptoms related to physical discomfort and systemic imbalance, particularly symptoms that may create noticeable physiological strain.

This medication is relevant in conditions characterized by periods of heightened symptoms and where short-term symptomatic assistance may be appropriate. It is commonly used to help with a brief listing of indications including symptoms related to inflammatory or irritative states, conditions involving episodic or fluctuating manifestations, and manifestations that interfere with daily functioning.

“It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.”

Staxom may be part of symptomatic management in clinical settings involving acute or unstable symptom patterns. It is relevant for managing symptoms that interfere with daily comfort and may assist patients with maintaining a sense of stability when symptoms are more noticeable.


Quick Fact: Symptom Support

Staxom is relevant for easing challenging symptomatic manifestations, especially those marked by increased discomfort or tension, which supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Staxom (Moxifloxacin) — Official Regulatory Information

This profile details the population eligibility and exclusion rules for systemic moxifloxacin (Staxom), based strictly on government regulatory documents.


Eligibility Scope

Eligibility Status Applicable Population/Condition
Populations for whom use is allowed Adults 18 years of age
Populations for whom use is contraindicated Patients under 18 years of age (pediatric)
Patients with known hypersensitivity to moxifloxacin or other quinolones
Pregnancy and lactation (breastfeeding)
Patients with a history of tendon disease related to previous quinolone treatment
Age-related eligibility rules Pediatric Use: Contraindicated (< 18 years). Geriatric Use: Requires special caution ( 60 years).
Condition-specific eligibility rules Severe Hepatic Impairment (Child-Pugh C): Contraindicated. Myasthenia Gravis: Use should be avoided. Renal Impairment: No dosage adjustment typically required.
Eligibility-related restrictions Contraindicated in patients with congenital or acquired QT prolongation, uncorrected hypokalaemia (low potassium), or clinically relevant bradycardia (slow heart rate).

Resulting Eligibility Structure

The eligibility for moxifloxacin is strictly defined by regulatory documents, limiting its use to adult patients whose clinical condition does not include a recognized contraindication. The medicine is absolutely prohibited for pediatric patients, pregnant or breastfeeding women, and individuals with defined cardiac conditions or severe liver impairment. Use is also restricted, requiring special caution, in groups such as the elderly due to the increased risk of tendon disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Staxom (moxifloxacin) is formally documented in regulatory sources and categorized by the potential impact on safety and drug exposure.


Contraindicated Combinations

Co-administration is strictly prohibited (contraindicated) with Class IA and Class III antiarrhythmics (e.g., quinidine, amiodarone) and other medicines that prolong the QTc interval. This restriction is due to an officially documented pharmacodynamic interaction that enhances the risk of serious ventricular arrhythmias, such as Torsade de Pointes. The risk is also heightened in patients with uncorrected hypokalemia.


Clinically Significant Pharmacokinetic Interactions

Interacting Agent Category Interaction Mechanism & Requirement (Official)
Multivalent Cation-Containing Products (Antacids, Sucralfate, Multivitamins/Minerals) Chelation leads to significantly reduced drug absorption and systemic exposure. The oral tablet must be administered at least 4 hours before or 8 hours after these products to minimize this effect.
Warfarin (Oral Anticoagulant) The anticoagulant effect may be enhanced. Regulatory documents require the monitoring of Prothrombin Time/INR when co-administered.

Other Documented Interaction Notes

  • Corticosteroids and NSAIDs are documented as having pharmacodynamic interactions. Use with systemic corticosteroids further increases the risk of tendon disorders and rupture. NSAIDs may increase the risk of CNS effects.
  • Metabolic Pathways: Moxifloxacin is officially documented not to inhibit major CYP enzymes ( CYP3A4, CYP2D6, etc.), implying a low likelihood of altering the concentration of other medicines metabolized by these pathways.
  • Population: The risk of tendon disorders is further increased in geriatric patients (ge 60 years) receiving concomitant corticosteroid therapy.

This interaction structure establishes mandatory administration constraints and high-risk prohibitions to manage cardiac and absorption-related risks, while providing clarity on the drug's limited role as a metabolic inhibitor.

Mechanism of Action

Dual Inhibition of Bacterial DNA Enzymes

The mechanism of moxifloxacin is defined by its interference with the essential genetic processes of bacterial pathogens, causing cell destruction. Moxifloxacin modulates the activity of two vital bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes manage the topology of the bacterial chromosome during replication. Moxifloxacin stabilizes the enzyme-DNA cleavage complex, which physically blocks the enzymes' ability to re-ligate the cut DNA strands.

Initiation of Lethal DNA Damage Cascade

The stabilization of the enzyme-DNA complex leads to a rapid accumulation of irreversible DNA double-strand breaks within the bacterial chromosome. The extensive genomic damage induced by the complex formation prevents the function of the microbe's repair systems, leading to a concentration-dependent bactericidal effect and subsequent cell death. The system-level consequence is the physical destruction of the pathogenic microbial population.

Constraint by Target-Site Resistance

The action of the mechanism is constrained by chromosomal point mutations in the genes encoding its target enzymes ( extitgyrA/gyrB or extitparC/parE). These mutations physically alter the binding site, which significantly reduces the drug's affinity and prevents the establishment of the lethal DNA-enzyme complex, allowing the mutated enzymes to sustain the pathogen's replication cycles.

Dosage and Administration Information

How to Use Staxom (Moxifloxacin) — Official Administration Guidelines

This information describes the required procedural steps and fixed dosing parameters for systemic moxifloxacin (often sold under brand names like Staxom or Avelox).


Dosing and Administration

The approved route of administration is either oral (tablet) or intravenous (IV) infusion. The standard dose for adults (18 years and older) is 400 mg once every 24 hours.

Route Standard Dose Frequency Duration
Oral Tablet 400 mg Once Daily Varies by indication (e.g., 5 to 21 days)
IV Infusion 400 mg Once Daily Varies by indication (e.g., 5 to 21 days)

Required Procedural Steps

  1. Oral Tablets: The film-coated tablet must be swallowed whole with liquid and must not be crushed, split, or chewed. Administration is independent of meals (with or without food).
  2. Timing Constraint: For the oral tablet, administration must occur at least 4 hours before or 8 hours after products containing multivalent cations (e.g., antacids, sucralfate, iron or zinc supplements) to prevent reduced absorption.
  3. IV Infusion: The solution for infusion must be administered slowly over a period of 60 minutes. Rapid injection or bolus administration is strictly prohibited.

Population and Missed Doses

  • Pediatric Use: Systemic moxifloxacin is generally not recommended for patients under 18 years of age.
  • Dose Adjustment: No dosage adjustment is typically required for elderly patients or those with mild to severe kidney impairment (including those on dialysis).
  • Missed Oral Dose: If a dose is missed, take it as soon as remembered, unless the next dose is due in less than 8 hours, in which case the missed dose should be skipped. Do not double the dose.

These instructions define the standardized approach to using the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Staxom

The clinical evaluation of Staxom (moxifloxacin) was evaluated in numerous large, formal studies, including Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were designed to examine the medicine's use in various systemic bacterial infections and to report on measurements of clinical and bacteriological outcomes. Research provides context but not individual predictions, as findings describe group patterns, not personal outcomes.


Evidence for use in Community-Acquired Pneumonia (CAP)

Research for Community-Acquired Pneumonia has been conducted through extensive, multi-center trials and subsequent pooling of data in Systematic Reviews. Researchers monitored key outcomes related to clinical treatment—used in research exploring how symptoms change over time—and bacteriological eradication, applied in studies examining the presence of the causative microbe.

Studies monitored patient responses at the end of treatment and again at follow-up visits, typically several weeks later, to report on sustained measurements of outcomes related to infection. Some pooled research reported specific measurements of bacteriological eradication in comparison to other drug types, with documented differences observed in these trials.


Evidence for use in Acute Bacterial Exacerbation of Chronic Bronchitis (AECB)

The evidence base for acute worsening of Chronic Bronchitis relies on double-blind Randomized Controlled Trials which explored short-term symptom changes. Study outcomes examined focused on clinical outcomes (resolution or improvement of key respiratory symptoms like increased sputum volume) and microbiological outcomes (applied in studies examining the presence of the infecting bacteria).

Research reported various rates of clinical outcomes. A key limitation is that regulatory guidance for the use of this class of antibiotics in AECB recommends that it be reserved for patients who have no alternative treatment options. This guidance is based on safety concerns associated with the entire drug class, which contextualizes the research findings for this specific infection.


Uncertainty and Research Gaps

The regulatory evidence landscape highlights areas where certainty remains low or where research is limited. The most significant gap is in the pediatric population. The safety and effectiveness of the systemic use of moxifloxacin in children under 18 remains insufficiently studied in large-scale efficacy trials, and research for this population is limited. Furthermore, the mandatory regulatory restriction on reserving this drug for certain less-severe infections, such as Acute Bacterial Sinusitis and AECB, limits the clinical data available for broader application.

Key Studies & References

  1. Moxifloxacin - StatPearls Publishing
  2. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials (DARE Abstract)

Frequently Asked Questions (FAQ)

Common questions about Staxom (FAQ)

Q: Is Staxom a common drug, or is it new?

A: Staxom, whose active ingredient is moxifloxacin, is not considered a new drug. According to regulatory documents, the medicine was first approved in 1999 in the United States. It belongs to the established class of antibiotics known as fluoroquinolones.


Q: Does Staxom work immediately, or does it take time to build up in your system?

A: The drug begins the process of affecting bacteria after administration. However, official product information suggests that the steady-state concentration—the amount needed for a consistent effect across the body—is typically achieved after approximately three days of once-daily dosing.


Q: What's the difference between Staxom and other similar medicines?

A: Staxom (moxifloxacin) is classified as a modern fluoroquinolone antibiotic. It is sometimes officially characterized as a respiratory fluoroquinolone, indicating its documented effectiveness against many bacteria that cause respiratory tract infections.


Q: Will Staxom definitely cure the condition, or just manage it?

A: Staxom is used to treat susceptible bacterial infections. Its mechanism is described as bactericidal, meaning its action is designed to destroy the bacterial cells themselves and eradicate the infection rather than simply managing symptoms.


Q: Is it normal to feel a little dizzy when first starting Staxom?

A: Yes, dizziness is a documented common side effect of Staxom. Official regulatory information lists dizziness among the most frequent adverse reactions reported in clinical trials. The occurrence of dizziness is documented in patient information.


Q: How long does one dose of Staxom typically stay active in the body?

A: According to the official pharmacokinetics data, a dose of moxifloxacin has an average elimination half-life of approximately 12 hours in the plasma. This measure of how long the drug remains in the body supports its prescribed use as a once-daily medicine.


Q: What are the most commonly reported side effects people mention for Staxom?

A: The most common adverse reactions reported by patients in clinical trials are nausea, diarrhea, headache, and dizziness. These are the effects that official documents list as occurring in at least 3% of users.


Q: Can Staxom cause stomach upset or nausea?

A: Yes, nausea, vomiting, diarrhea, and abdominal pain are all listed as common adverse reactions in the official product information. Official administration instructions indicate the tablet may be taken with or without food.


Q: What happens if you accidentally miss a dose of Staxom?

A: Official instructions for the oral tablet advise taking a missed dose as soon as remembered, unless the next dose is due in less than 8 hours, in which case the missed dose should be skipped. Official instructions state that a double dose must not be taken.


Q: Does taking Staxom with common pain relievers cause problems?

A: Yes, regulatory documents note a potential interaction. Taking Staxom along with non-steroidal anti-inflammatory drugs (NSAIDs), a category that includes many common pain relievers, may increase the risk of side effects affecting the Central Nervous System (CNS).


Q: Are there any specific foods or drinks you should avoid while taking Staxom?

A: The oral tablet must be taken at least 4 hours before or 8 hours after any products containing multivalent cations, such as antacids, sucralfate, or supplements containing iron or zinc. Some official patient information also notes that alcohol consumption may potentially increase certain side effects, such as dizziness.


Q: Is it okay to drive or operate machinery while on Staxom?

A: Official warnings note the potential for Staxom to cause side effects such as dizziness, lightheadedness, and visual disturbances. Individuals should not drive or operate complex machinery until they know how the medicine affects them.


Q: How common are serious side effects with Staxom?

A: Serious adverse reactions, such as tendon rupture and peripheral neuropathy (nerve damage), are officially documented in the 'Warnings and Precautions' sections. These events are generally less frequent than common side effects, but are officially noted as potentially severe.


Q: Why do some people say Staxom didn't work for them?

A: Official product information documents that the drug's effectiveness is constrained by the target bacteria. Treatment failure can sometimes be due to chromosomal point mutations in the bacteria’s genetic material. These changes can reduce the drug’s ability to bind, making the bacteria resistant.


Q: Are there different strengths of Staxom available?

A: According to official regulatory documents, moxifloxacin is supplied as an oral tablet and a solution for intravenous infusion. Both forms typically contain 400 mg of the active ingredient.


Q: Does Staxom have a generic version available?

A: Yes, the active ingredient in Staxom, moxifloxacin hydrochloride, is available in generic versions. Regulatory bodies approve these generics as bioequivalent to the brand-name product, meaning they work in the same way in the body.


Q: Is Staxom addictive or habit-forming?

A: Staxom is a fluoroquinolone antibiotic and is not classified as a controlled substance by regulatory agencies. This classification indicates that the drug is not considered addictive or habit-forming.


Q: What's the difference between the brand name and generic versions of Staxom?

A: Regulatory standards require the generic version of moxifloxacin to have the identical active ingredient as the brand name (Staxom) and be proven to work in the body with the same effectiveness. While the inactive ingredients may differ, the drug itself is considered therapeutically equivalent.


Q: How soon after stopping Staxom can you start another medication?

A: The drug’s mean half-life is approximately 12 hours. This pharmacokinetic information is a key piece of data used by prescribers to determine appropriate intervals for starting subsequent medications.


Q: Is Staxom available over the counter in some countries?

A: In major markets like the United States, Staxom is strictly classified as a prescription-only medication. Official regulatory guidance only addresses its status in those markets and does not specify its classification in other countries.


Q: Do you have to take Staxom at the same exact time every day?

A: The official instructions require the medicine to be taken once every 24 hours. While consistency is important, the rules for a missed dose provide a degree of flexibility, as they state that a dose should be skipped only if the next dose is due within 8 hours.


Q: Will taking Staxom affect my ability to exercise?

A: Official warnings note that the drug is associated with a risk of tendinitis and tendon rupture. This can occur during or even months after treatment. This documented risk is relevant to individuals considering strenuous physical activity.

How should Staxom be stored and disposed of?

How to Store and Dispose of Staxom

Staxom (moxifloxacin) must be stored and handled according to official regulatory specifications to maintain its stability and integrity.

Storage Requirements

Staxom tablets should be kept at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The medicine must be stored in its original packaging and protected from moisture and light.

Child Protection and Disposal

All forms of Staxom must be kept out of the reach of children and pets and should be stored securely. Unused or expired medication should be disposed of by following specific guidance.

The preferred method of disposal is through a drug take-back program. If a program is unavailable, non-controlled medicines can be disposed of in household trash after mixing with an undesirable substance. Used syringes from the intravenous form must be placed in an FDA-cleared sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Staxom found in:

A-Z Index: